97105 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses Hepadnaviridae, e.g. hepatitis B virus
HEPATITIS B ANTIBODIES
#2MICE THAT MAKE VL BINDING PROTEINS
#3COMBINATION HBV THERAPY
#4HBV Surface Antigen Specific T Cell Receptors And Uses Thereof
#5Fc VARIANTS WITH ALTERED BINDING TO FcRn
#6BISPECIFIC ANTIBODIES FOR HBV SURFACE ANTIGEN (HBSAG) AND CD3 AND USES THEREOF
#7ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF
#8COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES
#9Fc VARIANTS WITH ALTERED BINDING TO FcRn
#10METHODS FOR OBTAINING ANTIBODY MOLECULES BINDING TO A PEPTIDE-MHC INTERFACE
#11EPITOPE PEPTIDE AND ANTIBODY FOR TREATING HBV INFECTION AND RELATED DISEASES
#12METHODS FOR ELIMINATING HEPATITIS B VIRUS CCCDNA AND RCDNA AND THE HEPATITIS B DRUGS USED IN THE METHODS THEREOF
#13ANTI-RNA VIRUS PARTICLE ANTIBODY OF HBV
#14TARGETED DRUG DELIVERY-RELEASE AND KILLING OF DRUG RESISTANT TUMORS AND PATHOGENS
#15Fc VARIANTS WITH ALTERED BINDING TO FcRn
#16GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND USES THEREOF
#17Anti-HBsAg antibody for treatment of chronic hepatitis D
#18HEPATITIS B VIRUS ANTIVIRUS (HBV-ANTIVIRUS) COMPOSITIONS AND METHODS OF USE
#19Fc VARIANTS WITH ALTERED BINDING TO FcRn
#20ANTI-HBV ANTIBODIES AND USES THEREOF
#21HEPATITIS B ANTIBODIES
#22HUMAN ANTIBODY SPECIFICALLY BINDING TO BINDING SITE OF HEPATOCYTE RECEPTOR OF HEPATITIS B VIRUS PRES1 ANTIGEN, AND USE THEREOF
#23Fc VARIANTS WITH ALTERED BINDING TO FcRn
#24ANTIBODIES, FRAGMENTS OR DERIVATIVES SPECIFICALLY BINDING TO A PROTEIN ANTIGEN CAPABLE OF BINDING TO NUCLEIC ACIDS AND USES OF SAME
#25ENGINEERING BACILLUS SUBTILIS AS A VERSATILE AND STABLE PLATFORM FOR PRODUCTION OF NANOBODIES
#26COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION
#27Biological Therapeutics for Infection-Relating Disorders or Conditions
#28Glucagon-like peptide 1 receptor agonists and uses thereof
#29ANTI-HBV ANTIBODIES AND METHODS OF USE
#30ANTIBODY BASED GENE THERAPY WITH TISSUE-DIRECTED EXPRESSION
#31Antibodies that potently neutralize hepatitis B virus and uses thereof
#32ANTIBODY BINDING TO HEPATITIS B VIRUS SURFACE ANTIGEN AND APPLICATION OF ANTIBODY
#33SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES
#34ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF
#35ANTIGEN BINDING POLYPEPTIDES, ANTIGEN BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF
#36DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HEPATITIS B VIRUS
#37METHOD AND ANTIBODY FOR DETECTION OF HBCAG
#38Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#39ANTIBODY COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION
#40Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#41COMPOSITIONS AND METHODS RELATED TO HUMAN NEUTRALIZING ANTIBODIES TO HEPATITIS B
#42Fc VARIANTS WITH ALTERED BINDING TO FcRn
#43ANTI-PRE-S1 HBV ANTIBODIES
#44A METHOD OF TREATING HBV INFECTION BY USING ANTI-PRE-S1 HBV ANTIBODIES
#45ANTI-HEPATITIS B VIRUS ANTIBODIES AND USE THEREOF
#46Recombinant Polyclonal Proteins and Methods of Use Thereof
#47Method for controlling affinity of antibody for antigen, antibody whose affinity for antigen has been altered, and its production method
#48NOVEL ANTI-HEPATITIS B VIRUS ANTIBODY AND USES THEREOF
#49ARENAVIRUS VECTORS FOR HEPATITIS B VIRUS (HBV) VACCINES AND USES THEREOF
#50MICE THAT MAKE VL BINDING PROTEINS
#51BINDING MOLECULES SPECIFIC FOR HBV ENVELOPE PROTEIN
#52Antibodies that neutralize hepatitis B virus and uses thereof
#53CONFORMATIONAL EPITOPE OF HEPATITIS B SURFACE ANTIGEN AND ANTIBODY BINDING SPECIFICALLY THERETO
#54COMBINATION HBV THERAPY
#55Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
#56Method for efficiently inducing antibody, antibody and detection system for hepatitis virus
#57Glucagon-like peptide 1 receptor agonists and uses thereof
#58Fc variants with altered binding to FcRn
#59Hepatitis B antibodies
#60Systems and methods to produce B cells genetically modified to express selected antibodies
#61Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#62MICE THAT MAKE VL BINDING PROTEINS
#63Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#64Antibodies and fragments thereof that bind hepatitis B virus protein X
#65Fc VARIANTS WITH ALTERED BINDING TO FcRn
#66Fc VARIANTS WITH ALTERED BINDING TO FcRn
#67Antibodies that potently neutralize hepatitis B virus and uses thereof
#68CYCLIC DINUCLEOTIDES AS STING AGONISTS
#69Multi-valent hepatitis B virus antigen binding molecules and uses thereof
#70BINDING MOLECULES TARGETING PATHOGENS
#71T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides
#72Fc VARIANTS WITH ALTERED BINDING TO FcRn
#73Fc VARIANTS WITH ALTERED BINDING TO FcRn
#74EX VIVO ANTIGEN-PRESENTING CELLS OR ACTIVATED CD-POSITIVE T CELLS FOR TREATMENT OF INFECTIOUS DISEASES
#75Anti-pre-S1 HBV antibodies
#76PROCESS OF CLONING AND FURTHER PURIFICATION TO MAKE A RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN
#77ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE
#78Antibody against hepatitis B surface antigen and use thereof
#79PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF
#80ERYTHROID CELLS COMPRISING ARGINASE
#81ERYTHROID CELLS COMPRISING ARGININE DEIMINASE
#82Erythroid cells comprising phenylalanine ammonia lyase
#83ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE
#84ERYTHROID CELLS COMPRISING LYSINE OXIDASE
#85Antibodies and fragments thereof that bind hepatitis B virus protein X
#86Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
#87CYTOMEGALOVIRUS ANTIGENS AND USES THEREOF
#88Biological therapeutics for infection-relating disorders or conditions
#89SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
#90Antibody based gene therapy with tissue-directed expression
#91Synthetic membrane-receiver complexes
#92Glucagon-like peptide 1 receptor agonists and uses thereof
#93Antibodies that potently neutralize hepatitis B virus and uses thereof
#94METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES
#95Means and methods for treating HBV infection and associated conditions
#96SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
#97Methods and compositions for eliciting an immune response against hepatitis B virus
#98Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#99SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
#100Synthetic membrane-receiver complexes
#101SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
#102SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
#103Method for controlling affinity of antibody for antigen, antibody whose affinity for antigen has been altered, and its production method
#104Fc VARIANTS WITH ALTERED BINDING TO FcRn
#105Anti-Pre-S1 HBV antibodies
#106Synthetic membrane-receiver complexes
#107Multi-valent hepatitis B virus antigen binding molecules and uses thereof
#108BINDING MOLECULES TARGETING PATHOGENS
#109ANTI-PRE-S1 HBV ANTIBODIES
#110Trispecific binding molecules for treating HBV infection and associated conditions
#111Synthetic membrane-receiver complexes
#112COMPOSITION AND USES THEREOF
#113Method for producing antibody reagent
#114Polypeptides and antibodies for treating HBV infection and related diseases
#115Synthetic membrane-receiver complexes
#116Cytomegalovirus antigens and uses thereof
#117Epitope of hepatitis B virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis B virus
#118METHOD FOR DETERMINING DELETIONS IN HBV PRE-S2 REGION
#119Antibody binding specifically to pre-S1 of hepatitis B virus and use of the antibody
#120ANTIBODY COMPOSITION FOR PREVENTION OR TREATMENT OF MUTANT HEPATITIS B VIRUS INFECTION
#121Mice that make Vbinding proteins
#122Methods of curing HBV infection and providing complete protection against HBV infection
#123Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
#124PROCESS OF CLONING AND FURTHER PURIFICATION TO MAKE A RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN
#125Means and methods for treating HBV infection and associated conditions
#126ANTIBODIES WITH ENHANCED OR SUPPRESSED EFFECTOR FUNCTION
#127Composition and uses thereof
#128Biological therapeutics for infection-relating disorders or conditions
#129METHODS AND KITS FOR THE DETECTION OF VIRAL INFECTIONS
#130Synthetic membrane-receiver complexes
#131Polypeptides and antibodies for treating HBV infection and related diseases
#132Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof
#133Fc variants with altered binding to FcRn
#134Polyclonal bispecific antibody compositions and method of use
#135Antibody composition for prevention or treatment of mutant hepatitis B virus infection
#136Antibodies and method for determining deletions in HBV pre-S region
#137Human antibodies specifically binding to the hepatitis B virus surface antigen
#138Nucleic acid construct comprising nucleic acid derived from genome of hepatitis C virus of genotype 1B, hepatitis C virus genome-replicating cells transfected with the same, and method for producing infectious hepatitis C virus particles
#139Subcutaneous administration of anti-hepatitis B antibodies
#140MICE THAT MAKE VL BINDING PROTEINS
#141Mice that make VL binding proteins
#142HUMANIZED ANTIBODY AND PROCESS FOR PREPARING SAME
#143Epitope and its use of hepatitis B virus surface antigen
#144ANTI-MHC ANTIBODY ANTI VIRAL CYTOKINE FUSION PROTEIN
#145Hepatitis B virus specific antibody and uses thereof
#146Methods and reagents for creating monoclonal antibodies
#147Polyclonal bispecific antibody compositions and method of use
#148Human antibodies specifically binding to the hepatitis B virus surface antigen
#149Methods and compositions for eliciting an immune response against hepatitis B virus
#150Molecular Antigen Array
#151Mice that make VL binding proteins
#152Fc variants with altered binding to FcRn
#153Molecular Antigen Array
#154Fc variants with altered binding to FcRn
#155Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus
#156Angiotensin peptide-carrier conjugates and uses thereof
#157Humanized high affinity recombinant antibody against Hepatitis B surface antigen
#158Stabilized anti-hepatitis B (HBV) antibody formulations
#159THERAPEUTIC AND DIAGNOSTIC AFFINITY PURIFIED SPECIFIC POLYCLONAL ANTIBODIES
#160SELECTION OF HUMAN MONOCLONAL ANTIBODIES BY MAMMALIAN CELL DISPLAY
#161AFFINITY TAG
#162USE OF HUMAN ANTIBODY CAPABLE OF NEUTRALIZING HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B VIRUS INFECTION
#163Method for analysis of hepatitis B virus s antigen
#164FC VARIANTS WITH ALTERED BINDING TO FCRN
#165Fc variants with altered binding to FcRn
#166Fc variants with altered binding to FcRn
#167Fc variants with altered binding to FcRn
#168FC variants with altered binding to FCRN
#169Fc variants with altered binding to FcRn
#170CROSS-SPECIES-SPECIFIC BINDING DOMAIN
#171Recombinant Mouse-Human Chimeric Fab Against Hepatitis B Surface Antigen
#172Subcutaneous administration of anti-hepatitis B antibodies
#173Transgenic Mice and Use Thereof as an Experimental Model
#174DETECTING HEPATITIS B VIRUS
#175Rabbit monoclonal antibodies to hepatitis B surface antigens and methods of using the same
#176Microwell array chip for detecting antigen-specific lymphocytes, method of detecting and method of manufacturing antigen-specific lymphocytes, and method of cloning antigen-specific lymphocyte antigen receptor genes
#177Fc variants with altered binding to FcRn
#178Powerful vaccine composition comprising lipopeptide and poly I:C as an adjuvant
#179Antigen Arrays for Treatment of Allergic Eosinophilic Diseases
#180Fc variants with altered binding to FcRn
#181Human Polyclonal Antibodies from Genetically Engineered Animals
#182Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
#183Molecular antigen arrary
#184Method of detecting hepatitis B virus s antigen
#185Viral variants
#186Stabilized anti-hepatitis B (HBV) antibody formulations
#187Method for detecting or measuring HBV
#188Method of Antibody Production
#189Antigen arrays for treatment of bone disease
#190Antigen arrays for treatment of allergic eosinophilic diseases
#191Production of humanized antibodies in transgenic animals
#192Angiotensin peptide-carrier conjugates and uses thereof
#193Continuous in-vitro evolution
#194Molecular antigen array
#195Specificity exchangers that redirect antibodies to a pathogen
#196Humanized antibody and process for preparing same
#197Anti-HBs monoclonal antibody
#198Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues
#199Microwell array chip for detecting antigen-specific lymphocytes, method of detecting and method of manufacturing antigen-specific lymphocytes, and method of cloning antigen-specific lymphocyte antigen receptor genes
#200Specificity exchangers that redirect antibodies to a pathogen
#201Angiotensin peptide-carrier conjugates and uses thereof
#202Synthetic peptides that bind to the hepatitis B virus core and E antigens
#203Humanized antibody against S-surface antigen of hepatitis B virus
#204Rabbit monoclonal antibodies to hepatitis B surface antigens and methods of using the same
#205Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
#206Treatment of hepatitis B virus infection with human monoclonal antibodies
#207Variable region of the monoclonal antibody against the HBV S-surface antigen and a gene encoding the same
#208Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
#209Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
#210Chimeric antigens for breaking host tolerance to foreign antigens
#211Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis